These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1482710)

  • 21. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions.
    Rini BI; Selk LM; Vogelzang NJ
    Clin Cancer Res; 1999 Oct; 5(10):2766-72. PubMed ID: 10537340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major histocompatibility gene therapy: the importance of haplotype and beta 2-microglobulin.
    Salamone FN; Gleich LL; Li YQ; Stambrook PJ
    Laryngoscope; 2004 Apr; 114(4):612-5. PubMed ID: 15064612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA-B27, but not HLA-B7, immunodominance to influenza is ERAP dependent.
    Akram A; Lin A; Gracey E; Streutker CJ; Inman RD
    J Immunol; 2014 Jun; 192(12):5520-8. PubMed ID: 24835397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Technology evaluation: Allovectin-7, Vical.
    Galanis E
    Curr Opin Mol Ther; 2002 Feb; 4(1):80-7. PubMed ID: 11883699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic recombinant DNA delivery for cancer therapeutics.
    Felgner PL; Zaugg RH; Norman JA
    Cancer Gene Ther; 1995 Mar; 2(1):61-5. PubMed ID: 7621256
    [No Abstract]   [Full Text] [Related]  

  • 26. Co-expression of HLA-B7 and HLA-B27 alleles is associated with B7-restricted immunodominant responses following influenza infection.
    Akram A; Inman RD
    Eur J Immunol; 2013 Dec; 43(12):3254-67. PubMed ID: 24113999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human herpesvirus 6B immediate-early I protein contains functional HLA-A*02, HLA-A*03, and HLA-B*07 class I restricted CD8(+) T-cell epitopes.
    Iampietro M; Morissette G; Gravel A; Dubuc I; Rousseau M; Hasan A; O'Reilly RJ; Flamand L
    Eur J Immunol; 2014 Dec; 44(12):3573-84. PubMed ID: 25243920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck.
    Gleich LL; Gluckman JL; Nemunaitis J; Suen JY; Hanna E; Wolf GT; Coltrera MD; Villaret DB; Wagman L; Castro D; Gapany M; Carroll W; Gillespie D; Selk LM
    Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):775-9. PubMed ID: 11448348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary B cell repertoire remodeling to achieve humoral transplantation tolerance.
    Parsons RF; Redfield RR; Rodriguez E; Mustafa MM; Vivek K; Murayama M; Naji A; Noorchashm H
    Semin Immunol; 2012 Apr; 24(2):109-14. PubMed ID: 21978627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The alloantibody response in the allogeneically pregnant rat. IV. Analysis of the alloantibody specificities with monoclonal antibodies.
    Smith RN; Amsden A; Sudilovsky O; Coleman N; Margolies R
    J Immunol; 1986 Jun; 136(11):4063-9. PubMed ID: 3084652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene therapy: recent progress in the clinical oncology arena.
    Pandha HS; Martin LA; Rigg AS; Ross P; Dalgleish AG
    Curr Opin Mol Ther; 2000 Aug; 2(4):362-75. PubMed ID: 11249766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene therapy for head and neck cancer.
    Gleich LL
    Laryngoscope; 2000 May; 110(5 Pt 1):708-26. PubMed ID: 10807351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alloantigen gene therapy for head and neck cancer: evaluation of animal models.
    Gleich LL; Li YQ; Li S; Gluckman JL; Stambrook PJ
    Head Neck; 2003 Apr; 25(4):274-9. PubMed ID: 12658731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies on the induction of tolerance to alloantigens. III. Induction of antibodies directed against alloantigen-specific delayed-type hypersensitivity T cells by a single injection of allogeneic lymphocytes via portal venous route.
    Sato S; Qian JH; Kokudo S; Ikegami R; Suda T; Hamaoka T; Fujiwara H
    J Immunol; 1988 Feb; 140(3):717-22. PubMed ID: 2448373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
    Liu A; Hu P; Khawli LA; Epstein AL
    J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J; Chen Y; Moyana T
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.
    Bergen M; Chen R; Gonzalez R
    Expert Opin Biol Ther; 2003 Apr; 3(2):377-84. PubMed ID: 12662150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant DNA immunotherapy ameliorate established airway allergy in a IL-10 dependent pathway.
    Fonseca DM; Wowk PF; Paula MO; Campos LW; Gembre AF; Turato WM; Ramos SG; Dias-Baruffi M; Barboza R; Gomes E; Silva CL; Russo M; Bonato VL
    Clin Exp Allergy; 2012 Jan; 42(1):131-43. PubMed ID: 22093133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
    Lu J; Celis E
    Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of infectious immunodeficiency in BALB/c mice by serial transfer of lymphocytes immune to alloantigens.
    Kim BS; Hui KM
    J Immunol; 1985 Jul; 135(1):255-60. PubMed ID: 4039740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.